Introduction to Clinical Development

This course provides you with a general overview and understanding of why and how we do clinical drug development

21 Nov 2022

2 days course


10,000 DKK ex VAT
(app. 1,344 EUR ex VAT)


This course gives you a general overview and understanding of why clinical drug research is conducted the way it is today, how drugs are developed, how to monitor adverse drug reactions (ADRs), what monitoring during clinical trials entails and who is responsible for what during the entire process, from before the molecule has been discovered to the point where it is administered as a drug to patients.

Our course will combine teaching by experts, workshops and group work, meaning there will be plenty of opportunities for you to put your learning into practice and engage in discussions with your teachers and fellow students.


  • Definition of Target Product Profile
  • Clinical Development Plans
  • Clinical Development Phases
  • Study Design and use of Clinical Data
  • Pharmacovigilance During Development and After Marketing
  • Data Monitoring During Clinical Trials
  • Good Clinical Practice (GCP)


    Book any course* scheduled for a date in 2022 and bring a colleague along: 2 for the price of 1. Only valid for bookings made 2 May until 16 May.

    Sign up yourself and a colleague in the same order form – then we make sure only one course fee is charged.

    (*Networks and courses offered together with University of Copenhagen and CBS are not included.)

Read more

Course leader(s) & Lecturer(s)

  • Kirsten Harting
    Course leader
    Medical Doctor and Executive MBA


This course is relevant if you are new in the field of clinical drug development, or if you are not directly involved in conducting clinical trials, but need to have a general understanding of clinical drug development. It is also suitable for you if you are considering working with clinical trials in the future.

What you will learn

  1. The basic principles of clinical drug development
  2. Study designs and different phases of drug development (Pre-clinical, Phase I, II & III studies, post-marketing studies)
  3. The importance of pharmacovigilance during study conduct and post-marketing
  4. The importance of data monitoring during clinical trials according to ICH Good Clinical Practice (GCP)
  5. The regulatory requirements in the drug development life cycle and market authorization process

What your company will get

  1. An employee who understands the basic principles of clinical drug development
  2. An employee who understands the importance of data monitoring and data safety (pharmacovigilance)
  3. An employee who understands the regulatory requirements during drug development and the market authorization process
  4. An employee who can provide valuable input to all other team members involved in clinical drug development

Course calendar

Starting 21 Nov 2022
21 Nov 2022 8:30-16:00


  • Clinical development plans and Target Product Profiles
  • Why is clinical drug research conducted in the way it is today?
    • Historical background
    • Most important authorities and guidelines
  • Clinical drug research: From molecule to patient
    • Preclinical
    • Phase I, II and III
    • Study design
    • Clinical results
    • Stakeholders: roles and responsibilities
  • Practical experience with pharmacovigilance in clinical studies: Adverse drug reactions in phases I-III
  • Workshop
22 Nov 2022 8:30-16:00


  • Dialog with regulatory bodies
    • The regulatory process during development
    • Submission of documentation to authorities
    • Drug approval - marketing authorization
    • Regulatory procedures after approval - life cycle management
  • Clinical studies after approval
    • Phase IV studies
    • Why are further studies conducted after the drug has been approved?
    • How are they designed? (Reference to a study design)
    • Types of studies
    • Post Authorization Safety Studies (PASS), NonInterventional Studies (NIS)
    • Who conducts them (sponsors, competitors, investigators)?
  • Pharmacovigilance after marketing: How do you monitor adverse drug reactions (ADRs) in real life contexts?
  • ICH Good Clinical Practice (GCP) monitoring guidelines
    • Why is monitoring necessary?
    • How is monitoring done in practice?
    • Consent - Distribution of responsibility: the sponsor’s, the CRO’s, the site’s (e.g. management of trial medicine), and the authorities’ responsibility? (inspections)
    • Audits and inspections - being “inspection ready”
  • Workshop
Practical information


Registration deadline
14 Nov 2022
Lersø Parkallé 101
2100 København Ø
21 - 22 Nov
Sometimes things change. This is the expected programme.

Course information


Prior to the course you will get access to mandatory and optional readings via your personal Atrium log-in.

Please familiarize yourself with the mandatory readings before starting the course.


There are no prerequisites for this course, but we recommend that you have a Bachelor’s degree or similar as a minimum.


There is no examination for this course.

Course leader(s)

Kirsten Harting
Medical Doctor and Executive MBA

You may also be interested in these courses

WANT TO KNOW MORE or need help?

Contact Client Manager Christina Spangsberg at +45 39 15 09 22

Send me a message